ProMIS Neurosciences Inc. is trading 14.0% up today at $10.41, rebounding sharply after recent declines in early June despite a lack of new company-specific news.
- The move appears driven by speculative buying and thin liquidity in the small-cap biotech name, which can lead to outsized price swings.
- Broader U.S. equities are also trading higher, supporting a risk-on sentiment that is benefiting the stock's recovery.
- No new regulatory filings or clinical updates have been released to account for the double-digit gain.